$SLS
SELLAS Life Sciences Group, Inc.

2021 Q4 Form 10-Q Financial Statement

#000139047821000036 Filed on November 12, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q3
Revenue $0.00 $0.00 $0.00
YoY Change -100.0%
Cost Of Revenue $0.00 $0.00 $0.00
YoY Change
Gross Profit $0.00 $0.00 $0.00
YoY Change
Gross Profit Margin
Selling, General & Admin $2.526M $2.436M $2.125M
YoY Change -23.22% 14.64% -10.9%
% of Gross Profit
Research & Development $3.393M $4.541M $2.367M
YoY Change 22.49% 91.85% 31.57%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $5.919M $6.977M $4.492M
YoY Change -2.33% 55.32% 7.36%
Operating Profit -$5.919M -$6.977M -$4.492M
YoY Change 55.32%
Interest Expense $0.00 $2.000K $0.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net $4.784M -$110.0K $20.00K
YoY Change 1012.56% -650.0% -100.48%
Pretax Income -$6.835M -$7.085M -$4.470M
YoY Change 83.24% 58.5% 6.43%
Income Tax -$237.0K
% Of Pretax Income
Net Earnings -$6.598M -$7.085M -$4.473M
YoY Change 77.37% 58.39% 6.45%
Net Earnings / Revenue
Basic Earnings Per Share -$0.45 -$0.53
Diluted Earnings Per Share -$415.2K -$0.45 -$0.53
COMMON SHARES
Basic Shares Outstanding 15.89M shares 15.87M shares 8.418M shares
Diluted Shares Outstanding 15.87M shares 8.418M shares

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $21.36M $26.28M $8.200M
YoY Change -39.5% 220.5% -9.89%
Cash & Equivalents $21.36M $26.30M $8.200M
Short-Term Investments
Other Short-Term Assets $1.689M $2.693M $1.100M
YoY Change 237.8% 144.82% 0.0%
Inventory
Prepaid Expenses
Receivables $0.00 $0.00
Other Receivables $0.00 $0.00
Total Short-Term Assets $23.04M $28.97M $9.333M
YoY Change -37.59% 210.45% -8.6%
LONG-TERM ASSETS
Property, Plant & Equipment $723.0K $767.0K $900.0K
YoY Change -19.67% -14.78% 200.0%
Goodwill $1.914M $1.914M $1.914M
YoY Change 0.0% 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $594.0K $597.0K $700.0K
YoY Change -1.0% -14.71% 16.67%
Total Long-Term Assets $3.231M $8.978M $9.176M
YoY Change -64.59% -2.16% -18.6%
TOTAL ASSETS
Total Short-Term Assets $23.04M $28.97M $9.333M
Total Long-Term Assets $3.231M $8.978M $9.176M
Total Assets $26.28M $37.95M $18.51M
YoY Change -42.94% 105.05% -13.85%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.144M $2.545M $1.779M
YoY Change -53.96% 43.06% -52.74%
Accrued Expenses $2.640M $2.584M $2.304M
YoY Change 38.0% 12.15% 53.19%
Deferred Revenue $0.00 $0.00
YoY Change -100.0%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.982M $5.319M $4.219M
YoY Change -59.61% 26.07% -24.31%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $946.0K $5.787M $6.100M
YoY Change -82.8% -5.13% 24.49%
Total Long-Term Liabilities $946.0K $5.787M $6.100M
YoY Change -82.8% -5.13% 24.49%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.982M $5.319M $4.219M
Total Long-Term Liabilities $946.0K $5.787M $6.100M
Total Liabilities $5.928M $11.35M $10.56M
YoY Change -67.23% 7.42% -2.64%
SHAREHOLDERS EQUITY
Retained Earnings -$138.6M -$132.0M -$114.2M
YoY Change 17.56% 15.59% 21.84%
Common Stock $159.0M $158.6M $122.1M
YoY Change 8.97% 29.87% 17.03%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $20.35M $26.61M $7.948M
YoY Change
Total Liabilities & Shareholders Equity $26.28M $37.95M $18.51M
YoY Change -42.94% 105.05% -13.85%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income -$6.598M -$7.085M -$4.473M
YoY Change 77.37% 58.39% 6.45%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$4.976M -$5.878M -$3.630M
YoY Change -245.5% 61.93% -4.97%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 50.00K 2.242M 8.490M
YoY Change -99.79% -73.59% 4368.42%
NET CHANGE
Cash From Operating Activities -4.976M -5.878M -3.630M
Cash From Investing Activities
Cash From Financing Activities 50.00K 2.242M 8.490M
Net Change In Cash -4.926M -3.636M 4.860M
YoY Change -118.18% -174.81% -233.88%
FREE CASH FLOW
Cash From Operating Activities -$4.976M -$5.878M -$3.630M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001390478
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-33958
dei Entity File Number
EntityFileNumber
001-33958
dei Entity Registrant Name
EntityRegistrantName
SELLAS Life Sciences Group, Inc.
dei Entity Registrant Name
EntityRegistrantName
SELLAS Life Sciences Group, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-8099512
dei Entity Address Address Line1
EntityAddressAddressLine1
7 Times Square, Suite 2503,
dei Entity Address City Or Town
EntityAddressCityOrTown
New York,
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10036
dei City Area Code
CityAreaCode
(646)
dei Local Phone Number
LocalPhoneNumber
200-5278
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
SLS
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
15885542 shares
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
26281000 USD
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2593000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35302000 USD
CY2021Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
100000 USD
CY2020Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
100000 USD
CY2021Q3 us-gaap Capitalized Contract Cost Net Current
CapitalizedContractCostNetCurrent
0 USD
CY2020Q4 us-gaap Capitalized Contract Cost Net Current
CapitalizedContractCostNetCurrent
1128000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
395000 USD
CY2021Q3 us-gaap Assets Current
AssetsCurrent
28974000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
36925000 USD
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
767000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
896000 USD
CY2021Q3 sls In Process Research Development
InProcessResearchDevelopment
5700000 USD
CY2020Q4 sls In Process Research Development
InProcessResearchDevelopment
5700000 USD
CY2021Q3 us-gaap Goodwill
Goodwill
1914000 USD
CY2020Q4 us-gaap Goodwill
Goodwill
1914000 USD
CY2021Q3 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
597000 USD
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2545000 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4657000 USD
CY2020Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
614000 USD
CY2021Q3 us-gaap Assets
Assets
37952000 USD
CY2020Q4 us-gaap Assets
Assets
46049000 USD
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2584000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1913000 USD
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
190000 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
166000 USD
CY2021Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
0 USD
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
5600000 USD
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
5319000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12336000 USD
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
667000 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
825000 USD
CY2021Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
239000 USD
CY2020Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
239000 USD
CY2021Q3 sls Fair Value Of Warrants Potentially Settleable In Cash
FairValueOfWarrantsPotentiallySettleableInCash
84000 USD
CY2020Q4 sls Fair Value Of Warrants Potentially Settleable In Cash
FairValueOfWarrantsPotentiallySettleableInCash
55000 USD
CY2021Q3 sls Contingent Purchase Price Consideration Net Of Current Portion
ContingentPurchasePriceConsiderationNetOfCurrentPortion
5036000 USD
CY2020Q4 sls Contingent Purchase Price Consideration Net Of Current Portion
ContingentPurchasePriceConsiderationNetOfCurrentPortion
4633000 USD
CY2021Q3 us-gaap Liabilities
Liabilities
11345000 USD
CY2020Q4 us-gaap Liabilities
Liabilities
18088000 USD
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
145864000 USD
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000 shares
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000 shares
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15874131 shares
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15874131 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14254554 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14254554 shares
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
2000 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
1000 USD
CY2021Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
158610000 USD
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-132005000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-117904000 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
26607000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
27961000 USD
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
37952000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
46049000 USD
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 USD
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7600000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 USD
CY2021Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
0 USD
CY2020Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
0 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
200000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
0 USD
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4541000 USD
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2367000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12281000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6511000 USD
CY2021Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2436000 USD
CY2020Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2125000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
8794000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
6312000 USD
CY2021Q3 us-gaap Costs And Expenses
CostsAndExpenses
6977000 USD
CY2020Q3 us-gaap Costs And Expenses
CostsAndExpenses
4492000 USD
us-gaap Costs And Expenses
CostsAndExpenses
21275000 USD
us-gaap Costs And Expenses
CostsAndExpenses
12823000 USD
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6977000 USD
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4492000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-13675000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-12823000 USD
CY2021Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-30000 USD
CY2020Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-6000 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
29000 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-25000 USD
CY2021Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
2000 USD
CY2021Q3 sls Change In Fair Value Of Contingent Purchase Price Consideration
ChangeInFairValueOfContingentPurchasePriceConsideration
-140000 USD
CY2020Q3 sls Change In Fair Value Of Contingent Purchase Price Consideration
ChangeInFairValueOfContingentPurchasePriceConsideration
13000 USD
sls Change In Fair Value Of Contingent Purchase Price Consideration
ChangeInFairValueOfContingentPurchasePriceConsideration
-403000 USD
sls Change In Fair Value Of Contingent Purchase Price Consideration
ChangeInFairValueOfContingentPurchasePriceConsideration
-268000 USD
CY2020Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
0 USD
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
6000 USD
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
25000 USD
CY2021Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-108000 USD
CY2020Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
19000 USD
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-426000 USD
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-218000 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-7085000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-4473000 USD
us-gaap Net Income Loss
NetIncomeLoss
-14101000 USD
us-gaap Net Income Loss
NetIncomeLoss
-13041000 USD
CY2021Q3 sls Dividend Arising From Warrant Modifications
DividendArisingFromWarrantModifications
0 USD
CY2020Q3 sls Dividend Arising From Warrant Modifications
DividendArisingFromWarrantModifications
0 USD
sls Dividend Arising From Warrant Modifications
DividendArisingFromWarrantModifications
0 USD
sls Dividend Arising From Warrant Modifications
DividendArisingFromWarrantModifications
78000 USD
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-7085000 USD
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7085000 USD
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4473000 USD
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-4473000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-14101000 USD
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-14101000 USD
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-13119000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-13119000 USD
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.45
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.45
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.53
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.53
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.92
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.92
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.83
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.83
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15874076 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15874076 shares
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8418038 shares
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8418038 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15344210 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15344210 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7174859 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7174859 shares
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
33415000 USD
CY2021Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2000 USD
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
275000 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-7085000 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
26607000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
27961000 USD
sls Stock Issued During Period Value Common Stockand Warrants
StockIssuedDuringPeriodValueCommonStockandWarrants
9005000 USD
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3019000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
723000 USD
us-gaap Net Income Loss
NetIncomeLoss
-14101000 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
26607000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
3783000 USD
CY2020Q3 sls Stock Issued During Period Value Common Stockand Warrants
StockIssuedDuringPeriodValueCommonStockandWarrants
8492000 USD
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
146000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-4473000 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
7948000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
6093000 USD
sls Stock Issued During Period Value Common Stockand Warrants
StockIssuedDuringPeriodValueCommonStockandWarrants
14455000 USD
sls Stock Issued During Period Value Pre Funded Warrant
StockIssuedDuringPeriodValuePreFundedWarrant
4000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
437000 USD
us-gaap Net Income Loss
NetIncomeLoss
-13041000 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
7948000 USD
us-gaap Net Income Loss
NetIncomeLoss
-14101000 USD
us-gaap Net Income Loss
NetIncomeLoss
-13041000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
723000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
437000 USD
sls Change In Operating Lease Right Of Use Assets
ChangeInOperatingLeaseRightOfUseAssets
0 USD
sls Change In Operating Lease Right Of Use Assets
ChangeInOperatingLeaseRightOfUseAssets
98000 USD
sls Change In Fair Value Of Common Stock Warrants Issued In Connection With Various Equity Financings
ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings
-29000 USD
sls Change In Fair Value Of Common Stock Warrants Issued In Connection With Various Equity Financings
ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings
25000 USD
sls Change In Fair Value Of Contingent Purchase Consideration
ChangeInFairValueOfContingentPurchaseConsideration
-403000 USD
sls Change In Fair Value Of Contingent Purchase Consideration
ChangeInFairValueOfContingentPurchaseConsideration
-268000 USD
us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
-1128000 USD
us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
0 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2181000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
588000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2112000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2123000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
666000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1133000 USD
sls Increase Decrease In Contract With Customer Liability Net
IncreaseDecreaseInContractWithCustomerLiabilityNet
-5600000 USD
sls Increase Decrease In Contract With Customer Liability Net
IncreaseDecreaseInContractWithCustomerLiabilityNet
0 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-21045000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13841000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9005000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
14455000 USD
sls Proceeds From Stock Subscription Receivable
ProceedsFromStockSubscriptionReceivable
0 USD
sls Proceeds From Stock Subscription Receivable
ProceedsFromStockSubscriptionReceivable
308000 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
3019000 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
4000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
12024000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
14767000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-9021000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
926000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
35402000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7377000 USD
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
26381000 USD
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8303000 USD
us-gaap Proceeds From Interest Received
ProceedsFromInterestReceived
6000 USD
us-gaap Proceeds From Interest Received
ProceedsFromInterestReceived
25000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
976000 USD
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-132000000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-21000000 USD
us-gaap Net Income Loss
NetIncomeLoss
-14100000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2200000 USD
sls Increase Decrease In Contract With Customer Liability Net
IncreaseDecreaseInContractWithCustomerLiabilityNet
-5600000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1400000 USD
us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
-1100000 USD
sls Non Cash Charges
NonCashCharges
1200000 USD
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
26300000 USD
CY2021Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
100000 USD
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reclassification</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior year amounts have been reclassified to conform to current year presentation. These reclassifications had no effect on the Company's loss from operations, net loss, and net loss per share.</span></div>
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1294000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4242000 shares
CY2021Q3 sls Prepaid Research And Development
PrepaidResearchAndDevelopment
1842000 USD
CY2020Q4 sls Prepaid Research And Development
PrepaidResearchAndDevelopment
95000 USD
CY2021Q3 us-gaap Prepaid Insurance
PrepaidInsurance
691000 USD
CY2020Q4 us-gaap Prepaid Insurance
PrepaidInsurance
221000 USD
CY2021Q3 sls Prepaid Professional Services
PrepaidProfessionalServices
57000 USD
CY2020Q4 sls Prepaid Professional Services
PrepaidProfessionalServices
49000 USD
CY2021Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
3000 USD
CY2020Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
30000 USD
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2593000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
395000 USD
CY2021Q3 sls Contract Research Payable
ContractResearchPayable
1399000 USD
CY2020Q4 sls Contract Research Payable
ContractResearchPayable
631000 USD
CY2021Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
865000 USD
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
812000 USD
CY2021Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
39000 USD
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
276000 USD
CY2021Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
281000 USD
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
194000 USD
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2584000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1913000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
77000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
311000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
321000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
330000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1039000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
182000 USD
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
857000 USD
CY2020Q3 us-gaap Loss Contingency Claims Dismissed Number
LossContingencyClaimsDismissedNumber
2 complaint
us-gaap Loss Contingency Claims Settled Number
LossContingencyClaimsSettledNumber
3 case
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000 shares
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
558000 shares
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
526000 shares
CY2021Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
2062000 shares
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1392000 shares
sls Class Of Warrant Or Right Number Of Warrants Issued
ClassOfWarrantOrRightNumberOfWarrantsIssued
0 shares
sls Class Of Warrant Or Right Number Of Warrants Exercised
ClassOfWarrantOrRightNumberOfWarrantsExercised
833000 shares
sls Classof Warrantor Right Canceled Or Expired
ClassofWarrantorRightCanceledOrExpired
1000 shares
CY2021Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
558000 shares
CY2020Q4 sls Research And Development Arrangement Potential Milestone Payments To Be Received Maximum
ResearchAndDevelopmentArrangementPotentialMilestonePaymentsToBeReceivedMaximum
194500000 USD
CY2020Q4 sls Fair Value Of Warrants Liabilities
FairValueOfWarrantsLiabilities
55000 USD
sls Change In Fair Value Of Warrant Liabilities
ChangeInFairValueOfWarrantLiabilities
29000 USD
CY2021Q3 sls Fair Value Of Warrants Liabilities
FairValueOfWarrantsLiabilities
84000 USD
CY2020Q4 sls Research And Development Arrangement Cash Payment Received
ResearchAndDevelopmentArrangementCashPaymentReceived
7500000 USD
CY2020Q4 sls Research And Development Arrangement Royalties Payable Maximum Term
ResearchAndDevelopmentArrangementRoyaltiesPayableMaximumTerm
P15Y
CY2020Q4 sls Research And Development Arrangement Royalties Payable Minimum Term
ResearchAndDevelopmentArrangementRoyaltiesPayableMinimumTerm
P10Y
CY2020Q4 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
9500000 USD
CY2020Q4 sls Research And Development Arrangement Cash Payment Received
ResearchAndDevelopmentArrangementCashPaymentReceived
7500000 USD
CY2020Q4 sls Research And Development Arrangement Milestones Probable Of Being Achieved
ResearchAndDevelopmentArrangementMilestonesProbableOfBeingAchieved
2000000 USD
CY2021Q1 sls Proceeds From Research And Development Arrangement Milestone Payments
ProceedsFromResearchAndDevelopmentArrangementMilestonePayments
1000000 USD
CY2021Q2 sls Proceeds From Research And Development Arrangement Milestone Payments
ProceedsFromResearchAndDevelopmentArrangementMilestonePayments
1000000 USD
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
5600000 USD
sls Research And Development Arrangement Cash Payment Received
ResearchAndDevelopmentArrangementCashPaymentReceived
9500000 USD
sls Research And Development Arrangement Potential Milestone Payments To Be Received
ResearchAndDevelopmentArrangementPotentialMilestonePaymentsToBeReceived
192500000 USD
CY2021Q3 sls Contract With Customer Liability New Contract Revenue Recognized
ContractWithCustomerLiabilityNewContractRevenueRecognized
0 USD
sls Contract With Customer Liability New Contract Revenue Recognized
ContractWithCustomerLiabilityNewContractRevenueRecognized
7600000 USD
CY2021Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
9500000 USD
CY2020Q3 sls Contract With Customer Liability New Contract Revenue Recognized
ContractWithCustomerLiabilityNewContractRevenueRecognized
0 USD
sls Contract With Customer Liability New Contract Revenue Recognized
ContractWithCustomerLiabilityNewContractRevenueRecognized
0 USD
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
2000000 USD
sls Contract With Customer Liability New Contract Revenue Recognized
ContractWithCustomerLiabilityNewContractRevenueRecognized
7600000 USD
CY2021Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
0 USD
CY2021Q3 us-gaap Capitalized Contract Cost Gross
CapitalizedContractCostGross
1400000 USD
CY2021Q3 us-gaap Capitalized Contract Cost Amortization
CapitalizedContractCostAmortization
0 USD
us-gaap Capitalized Contract Cost Amortization
CapitalizedContractCostAmortization
1100000 USD
CY2020Q3 us-gaap Capitalized Contract Cost Amortization
CapitalizedContractCostAmortization
0 USD
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
13.38
us-gaap Capitalized Contract Cost Amortization
CapitalizedContractCostAmortization
0 USD
CY2021Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
0 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
200000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
0 USD
CY2020Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
0 USD
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
208000 shares
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y29D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
733000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
318000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
8.01
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
526000 shares
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.13
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y3D
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1722000 USD
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
101000 shares
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
21.72
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y3M
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
619000 USD
CY2021Q3 sls Closing Price Of Common Stock
ClosingPriceOfCommonStock
9.16
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
275000 USD
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
146000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
723000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
437000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0104
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.99
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0062
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.2129
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.0624
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y2M4D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M24D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.09
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.53
us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P10Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
2200000 USD
sls Employee Service Share Based Compensation Unrecognized Compensation Costs Weighted Average Period Of Recognition
EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition
P2Y9M25D

Files In Submission

Name View Source Status
0001390478-21-000036-index-headers.html Edgar Link pending
0001390478-21-000036-index.html Edgar Link pending
0001390478-21-000036.txt Edgar Link pending
0001390478-21-000036-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
sls-20210930.htm Edgar Link pending
sls-20210930.xsd Edgar Link pending
sls-20210930ex311.htm Edgar Link pending
sls-20210930ex312.htm Edgar Link pending
sls-20210930ex321.htm Edgar Link pending
sls-20210930_cal.xml Edgar Link unprocessable
sls-20210930_def.xml Edgar Link unprocessable
sls-20210930_g1.jpg Edgar Link pending
sls-20210930_htm.xml Edgar Link completed
sls-20210930_lab.xml Edgar Link unprocessable
sls-20210930_pre.xml Edgar Link unprocessable